PG-SH nanogels modified with TAT-SH have been shown to successfully enable miRNA delivery, mediating gene downregulation in multiple myeloma cells and delivering the antidiabetic peptide RS1-reg to enterocytes in vitro and in vivo (mouse model) after oral administration [36, 43]. Here, RS1 is linked to plasma cell myeloma.